Remaining innovative without sacrificing stability: An analysis of strategies in the Japanese pharmaceutical industry that enable firms to overcome inertia resulting from successful market penetration of new product development

Technovation

Volumn 22, Issue 12, 2002, Pages 747-759

  Takayama, M ^a,b   Watanabe, C ^b   Griffy Brown, C ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c PEPPERDINE UNIVERSITY   (United States)

Author keywords

Co evolution; Flexibility; Innovation; Institutional elasticity; New product development; Trade off

Indexed keywords

CUSTOMER SATISFACTION; DRUG PRODUCTS PLANTS; MARKETING; RESEARCH AND DEVELOPMENT MANAGEMENT;

INSTITUTIONAL ELASTICITY;

PRODUCT DEVELOPMENT;

EID: 0036888580     PISSN: 01664972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4972(01)00067-0     Document Type: Article

References (46)

1. Allen T.J. Studies of the problem-solving process in engineering design. IEEE Transactions on Engineering Management. 13(2):1966;72-83.
2. Bower J.L., Christensen M.C. Disruptive technologies: catching the wave. Harvard Business Review. January-February:1995.
3. Christensen M.C. The Innovator's Dilemma. 1997;Harvard Business School Press, Boston.
4. Clerk K.B., Fujimoto T. Product Development Performance. 1991;Harvard Business School Press, Boston.
5. Cockburn I., Henderson R. Racing to invest? The dynamics of competition in ethical drug discovery. Journal of Economics and Management Strategy. 3(3):1994;481-519.
6. Dimasi J.A., Hansen R.W., Grabowski H.G., Lasagna L. Cost of innovation in the pharmaceutical industry. Journal of Health Economics. 10:1991;107-142.
7. Dosi G. Technological paradigms and technological trajectories. Research Policy. 2(3):1982;147-162.
8. Dosi G. Technical Change and Industrial Transformation. 1984;Macmillan, London.
9. Dosi G.et al. Technical Change and Economic Theory. 1988;Pinter Publishers, London.
10. Freeman C. The Economics of Innovation. 2nd ed. 1982;Frances Pinter, London.
11. Fujimoto, T., 1993. In: Ito, H. (Ed.), Comparing Performance and Organization of Product Development across Firms, Regions and Industry: The Applicability of the Automobile Case.
12. Galbraith J.R., Nathanson D.A. Strategic Implementation: The Role of Structure and Process. 1978;West Publishing Co. London.
13. Grabowski H.G., Vernon J.M. A new look at the returns and risks to pharmaceutical R&D. Management Science. 36(7):1990;804-821.
14. Grabowski H.G., Vernon J.M. Returns to R&D on new drug introductions in the 1980s. Journal of Health Economics. 13:1994;383-406.
15. Hamel G., Prahalad C.K. Competing for the Future. Harvard Business Review. October-November:1994.
16. Hamel G., Prahalad C.K. Competing for the Future. 1994;Harvard Business Press, Boston.
17. Hamel, G., 2000. Leading the revolution. Harvard Business Review, Boston.
18. Henderson R., Cockburn I. Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management Journal. 15:1994;63-84.
19. Hammer M., Champy J. Reengineering the Corporation: A Manifesto for Business Revolution. 1993;Harper Business, New York.
20. Von Hippel, E., 1979. In: Baker (Ed.), A Customer Active Paradigm for Industrial Product Idea Generation.
21. Von Hippel The user's role in industrial innovation. Dean B., Goldhar J. Management of Research and Innovation. 1980;North Holland, Amsterdam.
22. Von Hippel E. Appropriability of innovation benefit as a predictor of the source of innovation. Research Policy. 2(2):1982;95-116.
23. von Hippel E. The Source of Innovation. 1988;Oxford Press, New York.
24. von Hippel E., Thomke S., Sonnack M. Creating breakthroughs at 3M. Harvard Business Review. September-October:1999.
25. IMS World Review, 1999. The Pharmaceutical Market. IMS Health, London.
26. JPMA (Japanese Pharmaceutical Manufacturers' Association), March 1999. Q&A about R&D. Tokyo, pp. 40-41.
27. JPMA (Japanese Pharmaceutical Manufacturers' Association), 2001. Data Book. Tokyo.
28. Von Krogh G., Ichijo K., Nonaka I. Enabling Knowledge Creation: How to Unlock the Mystery of Tacit Knowledge and Release the Power of Innovation. 2000;Oxford University Press, London.
29. Monthly Mix, April 1999. Trend of Anti-hypertensives, pp. 36-57.
30. Monthly Mix, September 1999. New Class of ATII Reaches the Top in Hypertensives with a 67.5% Prescription Rate for New Patients, pp. 66-68.
31. Nonaka I. The Knowledge-Creating Company. Harvard Business Review. November-December:1991;96-104.
32. Nonaka I., Takeuchi H. The Knowledge-Creating Company: How Japanese Companies Create the Dynamics of Innovation. 1995;Oxford University Press, Oxford.
33. Nonaka, I., Yamashita, Y., Kokubo, A., Sakuma, Y., 1997. Innovation Company, Diamond Inc.
34. Ohno T. The Toyota Production System. 1988;Productivity Press, Tokyo.
35. Pascale, R.T., Mileman, M., Gioja, L., 2000. Surfing the Edge of Chaos: The Laws of Nature and the New Laws of Business.
36. Pfeffer J., Sutton R.I. The Knowing-Doing Gap: How Smart Companies Turn Knowledge into Action. 2000;Harvard Business School Press, Boston.
37. Pharma Projects, 2001. V&O Publications. Surrey, UK.
38. Pisano G.P. The Development Factory. 1997;Harvard Business School Press, Boston.
39. Porter M.E. On Competition. 1998;Harvard Business School Press, Boston.
40. Porter M.E., Takeuchi H. Can Japan Compete? 2000;Harvard Business School Press, Boston.
41. Rogers E.M. Diffusion of Innovations. 4th ed. 1995;Free Press, New York.
42. Scrip Magazine February 2000. Leading Therapeutics in 1999. PJB Publications, London.
43. Takayama, M., Watanabe, C., 2001. Myth of market needs and technology seeds as a source of product innovation - an analysis of pharmaceutical new product development in anti-hypertensive product innovatio. Techonovation, in press.
44. Takayama, M., Watanabe, C., Griffy-Brown, C., 2001. The alliance strategy as competitive strategy for successively creative new product development - the proof of the co-evolution of creativity and efficiency in the Japanese pharmaceutical industry. Technovation, in press.
45. Utterback J.M. Mastering the Dynamics of Innovation - How Companies Can Seize Opportunities in the Face of Technological Change. 1994;Harvard Business Press, Boston.
46. Watanabe, C., Takayama, M., Nagamatsu, A., Tagami, T., Griffy-Brown, C., 2001. Technology spillover as a complement for high-level R&D intensity in the pharmaceutical industry. Technovation, in press.